The privately held biopharmaceutical company Inimex Pharmaceuticals has appointed Dr Michael Abrams president and CEO. In 1996, Dr Abrams led the establishment of AnorMED and served as the company's p
The rise in bacterial resistance has prompted a plethora of creative approaches to developing antibiotics. Only a few novel antibiotics have reached the market in the last 20 years or more, including
A preview of the emerging health care companies profiled in the current issue of START-UP: Windhover's Review of Emerging Medical Ventures . This month's profile group: Biotechs Battle Bacteria Forme